Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 1.00 |
| ▸ | SRC | P12931 | 12/20 | 0.80 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | ABL2 | P42684 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906312 | 1.00 | BTK (1.00) | BTKSRCEGFRABL1ABL2 | |
| SCHEMBL1898321 | 0.91 | BTK (1.00) | BTKSRCEGFRABL1ABL2 | |
| SCHEMBL1898318 | 0.91 | BTK (1.00) | BTKSRCEGFRABL1ABL2 | |
| SCHEMBL1907374 | 0.89 | SRC (1.00) | BTKSRCEGFRABL1ABL2 | |
| SCHEMBL1907372 | 0.89 | SRC (1.00) | BTKSRCEGFRABL1ABL2 | |
| SCHEMBL14673570 | 0.86 | BTK (1.00) | BTKSRCEGFRABL1KDR | |
| SCHEMBL12675515 | 0.86 | BTK (1.00) | BTKSRCEGFRABL1KDR | |
| SCHEMBL14673569 | 0.86 | BTK (1.00) | BTKSRCEGFRABL1KDR | |
| SCHEMBL1906420 | 0.86 | BTK (1.00) | BTKSRCEGFRABL1ABL2 | |
| SCHEMBL1906416 | 0.86 | BTK (1.00) | BTKSRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2558099-A2 | KINASE INHIBITORS | The Regents Of The University Of California, San Francisco (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045343-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | BTK 270/4885SRC 84/4885EGFR 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.